Ciprofloxacin once played a major role in treating certain sexually transmitted infections, but for most STIs encountered today, it is no longer the right drug. The CDC stopped recommending it for gonorrhea back in 2007 due to widespread resistance, and it was never effective against chlamydia or syphilis. The only STI for which ciprofloxacin remains a recognized treatment option is chancroid, a relatively uncommon genital ulcer disease. If you have been prescribed ciprofloxacin for an STI or are wondering whether leftover pills might work, the details matter quite a bit.
How Ciprofloxacin Works Against Bacteria
Ciprofloxacin belongs to the fluoroquinolone class of antibiotics. It kills bacteria by interfering with an enzyme called gyrase, which bacteria need to copy and maintain their DNA. When the drug locks onto gyrase, it stalls the machinery that unwinds and replicates DNA, ultimately causing lethal breaks in the bacterial chromosome.1PubMed Central. A Roadblock-and-Kill Mechanism of Action Model for the DNA-Targeting Antibiotic Ciprofloxacin This mechanism is effective against a broad range of bacteria, which is why ciprofloxacin became so popular for urinary tract infections, respiratory infections, and, for a time, gonorrhea. But that very popularity created intense selection pressure, driving resistance in the organisms it was most used against.
The Rise and Fall of Ciprofloxacin for Gonorrhea
When ciprofloxacin was first introduced for gonorrhea in the mid-1980s, it seemed like an ideal option. A single oral dose could cure the infection, sparing patients the need for injections. The initial dose was 250 mg, later bumped to 500 mg after treatment failures began appearing.2Journal of Antimicrobial Chemotherapy. The continuing evolution of antibiotic resistance in Neisseria gonorrhoeae: past, present and future threats to effective treatment For roughly two decades, fluoroquinolones were a go-to choice for gonorrhea around the world.
That era ended decisively. By the mid-2000s, the percentage of gonorrhea strains resistant to ciprofloxacin had climbed to the point where treatment failures were no longer rare exceptions. In 2007, the CDC formally pulled fluoroquinolones from its recommended gonorrhea treatment guidelines, citing widespread resistance across the United States.3PubMed. Update to CDC’s sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections This was not a minor tweak. It meant ciprofloxacin should not be used for gonorrhea at all, including for infections that also involve pelvic inflammatory disease.
The current recommended treatment for uncomplicated gonorrhea is a single intramuscular injection of ceftriaxone at 500 mg, with an antichlamydial drug added if chlamydia has not been ruled out.4Clinical Infectious Diseases. Management of Neisseria gonorrhoeae in the United States: Summary of Evidence From the Development of the 2020 Gonorrhea Treatment Recommendations and the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infection Treatment Guidelines That injection requirement is less convenient than swallowing a pill, but it reflects how limited the remaining effective options have become.
Gonorrhea Resistance Around the World
The resistance picture is uneven geographically, which partly explains why ciprofloxacin lingers in some treatment protocols overseas even after being abandoned in the US and Europe. A large systematic review found that ciprofloxacin resistance rates vary dramatically by continent. Asia had the highest rates at around 83%, compared with roughly 48% in Africa, 44% in Europe, 36% in South America, 24% in Oceania, and 17% in North America.5PubMed Central. Global trends of antimicrobial resistance rates in Neisseria gonorrhoeae: a systematic review and meta-analysis
WHO surveillance data from 2017–18 painted an even starker picture at the country level. Twelve countries across five WHO regions reported more than 90% resistance to ciprofloxacin in their gonorrhea samples. These included India, Thailand, Cambodia, South Korea, Pakistan, and several countries in South America and Africa. Only four countries reported resistance below 30%.6The Lancet Infectious Diseases. The World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): a retrospective observational study of data from 2017–18 For practical purposes, if you are being treated for gonorrhea anywhere in the world, ciprofloxacin is a gamble with poor odds.
Why Ciprofloxacin Does Not Work for Chlamydia
Chlamydia and gonorrhea are often lumped together in conversation, but the bacteria behind them are fundamentally different. Chlamydia trachomatis is an intracellular pathogen, meaning it lives and reproduces inside your cells rather than floating freely in tissue. Ciprofloxacin does penetrate cells to some extent, but not well enough to reliably eliminate chlamydia.
A clinical trial directly tested this in men with chlamydial urethritis. Even at high doses of 750 mg or 1,000 mg taken twice daily for a full week, ciprofloxacin failed badly. Among men who started with positive chlamydia cultures, the infection came back within four weeks in over half of those taking the lower ciprofloxacin dose and in about 38% of those on the higher dose. By contrast, none of the men treated with doxycycline had a recurrence.7JAMA. Ciprofloxacin Compared With Doxycycline for Nongonococcal Urethritis: Ineffectiveness Against Chlamymydia trachomatis due to Relapsing Infection The recurring strains were confirmed to be the same serotype as the originals, meaning these were true relapses rather than new infections. Ciprofloxacin was suppressing chlamydia temporarily without eliminating it.
The standard treatments for chlamydia remain doxycycline (typically for seven days) or azithromycin. If you are diagnosed with chlamydia and given ciprofloxacin, something has gone wrong with the prescribing decision.
Syphilis and Other STIs Ciprofloxacin Cannot Touch
Syphilis is caused by the spirochete Treponema pallidum, and penicillin has remained the treatment of choice for over seven decades. Ciprofloxacin has no meaningful activity against T. pallidum, and it has never been part of syphilis treatment guidelines. The same applies to viral STIs: ciprofloxacin is an antibiotic and has zero effect on herpes (HSV), HIV, hepatitis B, or human papillomavirus (HPV). Trichomoniasis, caused by a protozoan parasite rather than a bacterium, likewise falls outside ciprofloxacin’s reach and requires antiparasitic drugs like metronidazole.
The point worth emphasizing is that “STI” is an umbrella covering dozens of organisms with completely different biologies. Being a powerful antibiotic does not make ciprofloxacin relevant to most of them.
The One STI Where Ciprofloxacin Still Works Well
Chancroid, caused by the bacterium Haemophilus ducreyi, is one of the few sexually transmitted infections where ciprofloxacin remains a viable treatment. Chancroid produces painful genital ulcers and is more common in tropical regions than in the US or Europe. Clinical trials from the late 1980s found that a three-day course of ciprofloxacin (500 mg twice daily) achieved a 100% cure rate in men with culture-confirmed H. ducreyi infections.8PubMed Central. Evaluation of 500- and 1,000-mg doses of ciprofloxacin for the treatment of chancroid A separate randomized trial comparing single-dose and three-day ciprofloxacin regimens against trimethoprim-sulfamethoxazole confirmed that all three regimens worked, though the three-day ciprofloxacin course had the cleanest track record with no failures.9PubMed. Treatment of chancroid with ciprofloxacin. A prospective, randomized clinical trial
Chancroid is relatively rare in high-income countries today, so this indication does not come up often. But for travelers or people in endemic regions, it is worth knowing that ciprofloxacin remains an effective option here even as it has failed elsewhere.
Mycoplasma Genitalium and Fluoroquinolone Resistance
Mycoplasma genitalium has emerged as an increasingly recognized cause of urethritis and cervicitis, and it deserves separate attention because its relationship with fluoroquinolones is complicated. While some newer fluoroquinolones like moxifloxacin are used as second-line treatment for M. genitalium, ciprofloxacin specifically performs poorly. Laboratory testing of M. genitalium strains shows that ciprofloxacin has inherently high minimum inhibitory concentrations against this organism, regardless of whether resistance mutations are present in the bacterium’s DNA.10PLOS ONE. Mutations in ParC and GyrA of moxifloxacin-resistant and susceptible Mycoplasma genitalium strains In simpler terms, M. genitalium is naturally hard for ciprofloxacin to kill, and resistance mutations do not even change that picture much because the drug was never potent against it to begin with.
Adding to the concern, fluoroquinolone resistance in Mycoplasma and Ureaplasma urogenital infections has been climbing over time. A systematic review and meta-analysis found that roughly 60% of tested isolates were resistant to ciprofloxacin, the highest rate among the four fluoroquinolones studied.11Journal of Global Antimicrobial Resistance. Trends of fluoroquinolones resistance in Mycoplasma and Ureaplasma urogenital isolates: Systematic review and meta-analysis Moxifloxacin resistance was much lower at around 7%, which is why treatment guidelines favor moxifloxacin over ciprofloxacin for this particular organism when a fluoroquinolone is needed.
How Bacteria Develop Resistance to Ciprofloxacin
Understanding why ciprofloxacin stopped working for so many STIs comes down to how bacteria evolve under antibiotic pressure. Fluoroquinolone resistance develops through several routes. Bacteria accumulate mutations in the genes encoding gyrase and a related enzyme called topoisomerase IV, changing the drug’s target so it can no longer bind effectively. They also ramp up efflux pumps that actively push the drug back out of the cell before it can do damage. Some bacteria reduce the permeability of their outer membrane, making it harder for the drug to enter in the first place. On top of all that, resistance genes can spread between bacteria on small DNA elements called plasmids, allowing resistance to jump from one species to another.12Infectious Microbes and Diseases. Fluoroquinolone-Resistant Escherichia coli: Mechanisms of Resistance, Environmental Factors Influencing Resistance and Clinical Implications
The gonorrhea bacterium, Neisseria gonorrhoeae, has proven especially talented at acquiring resistance. It naturally takes up DNA from its environment, including resistance genes shed by other bacteria. Decades of ciprofloxacin use for gonorrhea gave N. gonorrhoeae ample opportunity to accumulate these defenses, and the results speak for themselves in the global resistance numbers described earlier.
Pelvic Inflammatory Disease and Combination Therapy
Pelvic inflammatory disease is an infection of the upper reproductive tract that can develop from untreated gonorrhea, chlamydia, or other bacterial infections. Because PID is often caused by a mix of organisms, treatment typically involves combination antibiotics. One study evaluating outpatient treatment of uncomplicated PID found that combining ciprofloxacin with tinidazole (an antiparasitic/anaerobic agent) achieved clinical effectiveness in about 97% of patients and successfully eliminated the targeted pathogens in most cases.13Reproductive health of woman. Evaluation of the effectiveness of outpatient treatment of uncomplicated pelvic inflammatory disease with the combination of ciprofloxacin and tinidazole
However, this represents a narrow scenario. CDC guidelines for PID in the United States do not include ciprofloxacin as a preferred agent, precisely because of the gonorrhea resistance issue. If N. gonorrhoeae is the underlying cause and it is resistant to ciprofloxacin, treating PID with a ciprofloxacin-based regimen could fail to clear the infection and allow it to progress to scarring and fertility problems. Any PID treatment protocol that includes ciprofloxacin should be used only in settings where gonorrhea has been ruled out or where local resistance patterns support its use.
Safety Risks Worth Knowing About
Even setting aside the resistance problem, ciprofloxacin carries safety concerns that have made health agencies increasingly cautious about prescribing it for mild or self-limiting infections. The FDA placed a black box warning on all systemic fluoroquinolones for the risk of tendinitis and tendon rupture. Between 1997 and 2006, the agency received reports of 268 tendon ruptures and 358 cases of tendinitis in patients taking these drugs, most involving the Achilles tendon.14PubMed Central. FDA adds “black box” warning label to fluoroquinolone antibiotics The risk is higher in people over 60, those taking corticosteroids, and organ transplant recipients.
Fluoroquinolones also carry a risk of peripheral neuropathy, which can involve numbness, tingling, or pain in the hands and feet that may persist after the drug is stopped. Case reports describe severe axonal nerve damage developing within days of starting ciprofloxacin.15PubMed Central. Severe Acute Axonal Neuropathy Induced by Ciprofloxacin: A Case Report The FDA has since added additional warnings for aortic aneurysm risk, mental health effects, and low blood sugar. None of this means ciprofloxacin is an unusually dangerous drug when used appropriately for serious infections, but it does mean that prescribing it for an STI that has better and safer alternatives is hard to justify.
Ciprofloxacin and Pregnancy
Fluoroquinolones are generally avoided during pregnancy due to concerns about fetal cartilage and joint development observed in animal studies. A pharmacovigilance analysis of FDA adverse event reports found some signals suggesting ciprofloxacin was associated with higher rates of certain rare congenital disorders, particularly coagulation-related and skin-related abnormalities, compared with azithromycin. However, rates of spontaneous abortion and most other congenital disorders were similar between ciprofloxacin and azithromycin.16Heliyon. Pregnancy related adverse events and congenital disorders associated with fluoroquinolones: A real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS)
For pregnant individuals who need STI treatment, safer alternatives exist for virtually every indication. Ceftriaxone covers gonorrhea, azithromycin or amoxicillin covers chlamydia in pregnancy, and penicillin remains the standard for syphilis. There is essentially no scenario where ciprofloxacin is the best STI treatment choice during pregnancy.
Why Ciprofloxacin Still Gets Prescribed for STIs
Despite all of this, ciprofloxacin continues to be prescribed for STIs in many settings, particularly in low- and middle-income countries. The reasons are practical: ciprofloxacin is cheap, widely available in generic form, and can be taken by mouth. In clinics that rely on syndromic management, where a healthcare worker treats based on symptoms rather than laboratory confirmation of the specific organism, broad-spectrum antibiotics like ciprofloxacin get used as a catch-all. Research from Uganda examining men treated for urethral discharge syndrome found that antibiotic overuse and poor stewardship were common, with patients frequently receiving drugs unlikely to match their actual infection.17PubMed Central. Antibiotic overuse, poor antimicrobial stewardship, and low specificity of syndromic case management in a cross section of men with urethral discharge syndrome in Kampala, Uganda
This creates a vicious cycle. Using ciprofloxacin against organisms that are already largely resistant accelerates resistance further, while failing to cure the patient’s infection. Affordable point-of-care diagnostics that can identify the specific pathogen would help break this cycle, but they remain unavailable in many of the settings where syndromic management is the norm.
What to Do If You Are Prescribed Ciprofloxacin for an STI
If a clinician prescribes ciprofloxacin and tells you it is for a sexually transmitted infection, ask what infection is being treated. For chancroid, the prescription makes sense. For anything else, it is reasonable to ask whether a more targeted option is available. If the diagnosis is gonorrhea, current evidence strongly favors ceftriaxone. If the diagnosis is chlamydia, doxycycline or azithromycin are the drugs with proven efficacy. If the diagnosis is uncertain and the provider is treating empirically, you can ask whether laboratory testing is available to identify the pathogen before committing to a particular antibiotic.
Self-treating with leftover ciprofloxacin from a previous prescription is a particularly bad idea. Even if the pills are not expired, the dose and duration for STIs differ from those used for urinary tract infections or other conditions ciprofloxacin is commonly prescribed for. Taking an insufficient course risks partial suppression of the infection without curing it, which can mask symptoms while the infection progresses or spreads to partners. And for the STIs most commonly encountered, the drug simply will not work regardless of how you take it.